Weight gain after stopping Eli Lilly’s new obesity treatment should help, not hurt the stock


David Ricks, CEO, Eli Lilly

Scott Mlyn | CNBC

Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell.

This article was originally published on CNBC